Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

China · Delayed Price · Currency is CNY

27.04

+1.03 (3.96%)

Sep 30, 2026, 3:00 PM CST

Market Cap	11.61B -40.0%
Revenue (ttm)	873.99M +371.4%
Net Income	-939.72M
EPS	-2.31
Shares Out	445.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,947,703
Open	26.28
Previous Close	26.01
Day's Range	25.90 - 27.92
52-Week Range	23.85 - 50.13
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provide... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Employees 1,356

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688062

Full Company Profile

Financial Performance

In 2025, SHA:688062's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -969.33 million, -7.14% less than in 2024.

Financial Statements